Hiroshi Aikata

机构：Hiroshima Prefectural Hospital · ORCID：0000-0002-3409-2156

发表论文 497 篇 · 总被引 19741 次 · h-index 65

代表论文

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 449)
• Targeting the liver clock improves fibrosis by restoring TGF-β signaling (2024 · Journal of Hepatology · 被引 60)
• Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma (2023 · Communications Medicine · 被引 37)
• A patient-derived HCC spheroid system to model the tumor microenvironment and treatment response (2024 · JHEP Reports · 被引 8)
• Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab (2023 · Oncology · 被引 8)
• Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study (2025 · Liver Cancer · 被引 7)